PMN today
$3.48-$0.28 (-7.45%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourDescending Triangle
1 hourStrong Bearish
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns up above $27.40
Key levels
Resistance$6.27
Resistance$4.50
Support$2.78
Latest news & SEC filings
SEC FilingProMIS Neurosciences Inc. filed a report on a major company event (Form 8-K)
EarningsProMIS Neurosciences posts smaller quarterly loss than expected
EarningsProMIS Neurosciences Posts Q3 2026 Financials
All PMN news →About ProMIS Neurosciences
ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapies for neurodegenerative diseases. Its lead candidate, PMN310, targets toxic misfolded amyloid beta oligomers in Alzheimer's disease, with additional programs in amyotrophic lateral sclerosis, Parkinson's disease, and other misfolded protein conditions. The company uses a computational platform to identify disease-specific epitopes on misfolded proteins and generate selective monoclonal antibodies. It operates in Canada and the United States and relies on third-party manufacturers and research partners.
Based on the company's 10-K filed Mar 25, 2026.
Nasdaq · Healthcare
ProMIS Neurosciences Inc. (PMN)
What Is the Price Target for PMN?
SEPT Low Target
$18.00
SEPT Mid Target
$19.00
SEPT High Target
$33.00
Analyst Consensus
$19.00
Is PMN a Buy or Sell Right Now?
Thesis
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PMN.
Start Free Trial →Is PMN Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$17.74
0
Moat Score
NONE
1/9
Piotroski Score
-34.1
Altman Z-Score
What Is Smart Money Doing with PMN?
Insider Signal
BUYING
10 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Williams Eugene | director | Buy | 26,500 | $91K | Nov 4, 2026 |
| Cashman Neil | director officer | Buy | 10,000 | $39K | Nov 2, 2026 |
| Williams Eugene | director | Buy | 1,316 | $5K | Oct 30, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PMN Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-959.7%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for PMN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PMN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:43:25 | $3.44 | 8,000 | $$27K | BUY |
| 20:22:42 | $3.45 | 5,000 | $$17K | MIDPOINT |
| 19:12:54 | $3.58 | 2,475 | $$9K | BUY |
| 19:11:43 | $3.46 | 3,718 | $$13K | SELL |
| 18:41:32 | $3.52 | 3,000 | $$11K | SELL |
5 dark pool trades shown · $$77K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ProMIS Neurosciences Inc. (PMN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PMN — frequently asked questions
What is PMN stock price today?
ProMIS Neurosciences Inc. (PMN) is at $3.48, down 7.45% (-$0.28) at the Nov 12, 2026 close.
Why is PMN stock moving today?
Latest PMN news — Nov 12, 2026: ProMIS Neurosciences Inc. filed a report on a major company event (Form 8-K) · Nov 12, 2026: ProMIS Neurosciences posts smaller quarterly loss than expected
What is the PMN price target?
The average analyst price target for PMN is $19.00, ranging from $18 to $33, based on 3 analysts. Latest: Chardan Capital maintains on Jul 28, 2026.
What do analysts rate PMN?
Analyst ratings for PMN: 0 Buy, 9 Hold, 0 Sell — consensus Hold.
Did PMN beat earnings?
PMN last reported on Aug 13, 2026: EPS -$1.28 vs -$1.38 expected — a beat of 7.2%.
Does PMN pay a dividend?
PMN does not currently pay a dividend.
What are PMN support and resistance levels?
Support: $2.78. Resistance: $4.50, $6.27, $7.74.
What are insiders doing with PMN?
Insider activity: BUYING, 10 buys and 0 sells in the last 90 days.
What is the latest news on PMN?
Nov 12, 2026: ProMIS Neurosciences Inc. filed a report on a major company event (Form 8-K) · Nov 12, 2026: ProMIS Neurosciences posts smaller quarterly loss than expected · Nov 12, 2026: ProMIS Neurosciences Posts Q3 2026 Financials